默克公司周一表示，将根据与中国SciBrunch Therapeutics达成的全球授权协议，支付高达21.3亿美元，以获得一种实验性癌症治疗药物的开发、生产和销售权。
Merck said on Monday it would pay up to $2.13 billion under a global licensing deal with China's SciBrunch Therapeutics for rights to develop, manufacture and sell an experimental cancer treatment.